SlideShare a Scribd company logo
1 of 22
Presented By:-
Sridhar S
1st M.Pharmacy
Pharmaceutical Regulatory
Affairs
JSS College Of Pharmacy
Mysuru-15
DEFINITION
 An FDA warning letter is an official message from the United
states Food & Drugs Administration (FDA) that it has found
that a manufacturer has violated some rule in a regulated
activity.
 While the FDA generally determines violations through its own
inspections, they can also issue one based on evidence from
state personnel
 the FDA does not consider a warning letter a final action on
which it can be issued
The FDA defines an FDA warning letter as:-
 “A correspondence that notifies regulated industry about violations
that FDA has documented during its inspections or investigations.
 Typically, a Warning Letter notifies a responsible individual or firm
that the Agency considers one or more products, practices, processes,
or other activities to be in violation of the Federal Food, Drug, and
Cosmetic Act (the Act), its implementing regulations and other
federal statutes.
 Warning Letters should only be issued for violations of regulatory
significance, i.e., those that may actually lead to an enforcement
action if the documented violations are not promptly and adequately
corrected. A Warning Letter is one of the Agency’s principal means
of achieving prompt voluntary compliance with the Act.
 The agency has a computer application called the Compliance
Management System (CMS) that district offices use to
electronically submit warning letter recommendations to FDA
Centers.
 All district office must use the CMS to submit the warning
letter recommendation, the Form FDA 483 that supports the
alleged violations, the Establishment Inspection Report (EIR),
and any written response from the firm.
WHY FDA COMES FOR INSPECTION
 The person who involved in the manufacturing of bulk
API or involved in the formulation of product are willing
to sale or market there product in the regions of the united
states
 The dossier is submitted according NDA for new product
and ANDA for generic drug and 502(f)(1) for
an API or bulk chemical
 After the dossier or application is accepted by the USFDA and
send a reply for the inspection of the premises
 FDA FORM 482- Notice Of Inspection
 It is an official notice of FDA for inspection signed by the FDA
officials. It is produced by the inspector and has the authority
to inspect the manufacturing facility
 Inspection coordinator will receive the notice and manage the
inspection accordingly
 Coordinator should ask for notice, if it is not presented by
the FDA inspector
 A copy of this shall be attached with the inspection file
FORM 482 shows that inspector has authorization from
FDA to inspect the facility
 An inspector can ask for the manufacturing records of the
regulated product and can enter in the area where the
product is being manufactured.
 He can review online records, collect samples and
interview the personnel working in area
 An inspector cant review the product price list, financial
data of firm, product marketing data, research documents
and employee data excluding the training records.
 These documents are considered as firms confidential
documents
 FDA FORM 483 – Observations of inspection
 Inspector shall provide the list of his observations about
inspection on FORM 483
 It has all the points noticed by the FDA inspectors. An
observation made in previous inspection or as mentioned in the
GMP are not followed or corrected can be added in 483
 The original copy of the FDA Form 483 is presented to the
form management, generally to the person who had received
the notice of inspection
 FDA Form 484- recipient of Samples
 During the inspection if FDA inspectors want to take any
sample they have to issue a receipt of those samples on
Form 484
 It has a quantity of simple with the lot number of the
product sampled Form 484 is used for samples only but
not for promotional material, labels, photographs or any
record taken by FDA investigators
TYPES OF WARNING LETTERS
 General FDA Warning Letters
 Tobacco Retailer Warning Letters
 Drug Marketing and Advertising Warning Letters (and
Untitled Letters to Pharmaceutical Companies)
General FDA Warning Letters
 When FDA finds that a manufacturer has significantly violated
FDA regulations, FDA notifies the manufacturer. This
notification is often in the form of a Warning Letter.
 The Warning Letter identifies the violation, such as poor
manufacturing practices, problems with claims for what a
product can do, or incorrect directions for use.
 The letter also makes clear that the company must correct the
problem and provides directions and a timeframe for the
company to inform FDA of its plans for correction.
 FDA then checks to ensure that the company’s
corrections are adequate. Matters described in FDA
warning letters may have been subject to subsequent
interaction between FDA and the recipient of the letter
that may have changed the regulatory status of the issues
discussed in the letter.
Tobacco Retail Warning Letters
 Compliance check inspections of tobacco retailers occur
periodically, and are conducted to determine a retail
establishment’s compliance with the Federal Food, Drug, and
Cosmetic Act, as amended by the Family Smoking Prevention
and Tobacco Control Act (Tobacco Control Act) and its
regulations in effect
 such as the Regulations Restricting the Sale and Distribution of
Cigarettes and Smokeless Tobacco to Protect Children and
Adolescents, found at Title 21 of the Code of Federal
Regulations, Part 1140
 21 C.F.R. Part 1140
CIGARETTES, SMOKELESS TOBACCO, AND COVERED
TOBACCO PRODUCTS
Prohibition of sale and distribution to the persons younger then
18yrs of age and Format and content requirements for labeling
and advertising.
 Tobacco products covered in compliance check inspections of
tobacco retailers include cigarettes and smokeless tobacco.
 All other Warning Letters issued by CTP for violations of the
Federal Food, Drug, and Cosmetic Act, as amended by the
Tobacco Control Act and its applicable regulations, can be
found at FDA’s main Warning Letter page at the Inspections,
Compliance, Enforcement, and Criminal Investigations -
Warning Letters page.
Drug Marketing and Advertising Warning
Letters
 These letters are supplied by the CDER Freedom
of Information Office (FOI). This page only covers letters
issued by Headquarters and the Office of Prescription Drug
Promotion (formerly the Division of Drug Marketing,
Advertising, and Communications).
 "Cyber" letters are sent electronically via the Internet to web
sites that offer to sell online prescription drugs that may be
illegal. The letters warn these web site operators that they may
be engaged in illegal activities and informs them of the laws
that govern prescription drug sales.
Warning Letter Close-Out Letter Program
 (Applies to letters issued on or after Sept. 1, 2009)
 FDA may issue a Warning Letter close-out letter ("close-out
letter") once the Agency has completed an evaluation of
corrective actions undertaken by a firm in response to a
Warning Letter.
 A close-out letter may issue when, based on FDA’s evaluation,
the firm has taken corrective action to address the violations
contained in the Warning Letter. This procedure applies to
Warning Letters issued on or after September 1, 2009.
 A close-out letter will not be issued based on representations
that some action will or has been taken. The corrective actions
must actually have been made and verified by FDA.
 If the Warning Letter contains violations that by their nature are
not correctable, then no close-out letter will issue.
 Future FDA inspections and regulatory activities may further
assess the adequacy and sustainability of these corrections.
Should violations be observed during a subsequent inspection
or through other means, enforcement action may be taken
without further notice
HOW TO BROWSE WARNING LETTERS
 Use any of these "Browse" functions:
 Browse Warning Letters by Company
 Browse Warning Letters by Issuing Office
 Browse Warning Letters by Subject
 Browse Warning Letters with Response Letters
 Browse Warning Letters with Closeout Letters
REFERENCE
 https://en.wikipedia.org/wiki/Form_FDA_483
 http://www.pharmaguideline.com/2014/11/fda-
forms-issued-in-inspections.html
 https://www.fda.gov/ICECI/EnforcementActions/Wa
rningLetters/ucm278624.htm
 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/c
fcfr/CFRSearch.cfm?CFRPart=1140

More Related Content

What's hot

Regulatory approval process for invitro diagnostics in us
Regulatory approval process for invitro diagnostics in usRegulatory approval process for invitro diagnostics in us
Regulatory approval process for invitro diagnostics in us
Vinod Raj
 

What's hot (20)

GMP compliances of Audit
GMP compliances of AuditGMP compliances of Audit
GMP compliances of Audit
 
Post Marketing Requirements/Complaince: PMRs and PMCs
Post Marketing Requirements/Complaince: PMRs and PMCsPost Marketing Requirements/Complaince: PMRs and PMCs
Post Marketing Requirements/Complaince: PMRs and PMCs
 
Good Automated Laboratory Practices
Good Automated Laboratory PracticesGood Automated Laboratory Practices
Good Automated Laboratory Practices
 
FDA Inspections ( How to Survive an FDA Inspection).ppt
FDA Inspections ( How to Survive an FDA Inspection).pptFDA Inspections ( How to Survive an FDA Inspection).ppt
FDA Inspections ( How to Survive an FDA Inspection).ppt
 
Auditing of manufacturing facilities by international regulatory agencies ppt
Auditing of manufacturing facilities by international regulatory agencies pptAuditing of manufacturing facilities by international regulatory agencies ppt
Auditing of manufacturing facilities by international regulatory agencies ppt
 
20210413 nvfg acs iso14155 13_apr2021
20210413 nvfg acs iso14155 13_apr202120210413 nvfg acs iso14155 13_apr2021
20210413 nvfg acs iso14155 13_apr2021
 
FDA Warning Letter
FDA Warning LetterFDA Warning Letter
FDA Warning Letter
 
Documentation in Pharmaceutical Industry Part I
Documentation in Pharmaceutical Industry Part I Documentation in Pharmaceutical Industry Part I
Documentation in Pharmaceutical Industry Part I
 
Fda Inspection
Fda InspectionFda Inspection
Fda Inspection
 
Prior Approval Supplements (PAS)
Prior Approval Supplements (PAS)Prior Approval Supplements (PAS)
Prior Approval Supplements (PAS)
 
NDA Application.pptx
NDA Application.pptxNDA Application.pptx
NDA Application.pptx
 
Submitting electronic Drug Master Files (DMF) and Active Substance Master Fil...
Submitting electronic Drug Master Files (DMF) and Active Substance Master Fil...Submitting electronic Drug Master Files (DMF) and Active Substance Master Fil...
Submitting electronic Drug Master Files (DMF) and Active Substance Master Fil...
 
Documentation in Pharmaceutical Industry.pptx
Documentation in Pharmaceutical Industry.pptxDocumentation in Pharmaceutical Industry.pptx
Documentation in Pharmaceutical Industry.pptx
 
Regulatory requirnment and approval procedure of drugs in japan ppt
Regulatory requirnment and approval procedure of drugs in japan pptRegulatory requirnment and approval procedure of drugs in japan ppt
Regulatory requirnment and approval procedure of drugs in japan ppt
 
International Medical Device Regulators Forum
International Medical Device Regulators ForumInternational Medical Device Regulators Forum
International Medical Device Regulators Forum
 
MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...
MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...
MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...
 
National Sanitation Foundation(NSF) Certification
National Sanitation Foundation(NSF) CertificationNational Sanitation Foundation(NSF) Certification
National Sanitation Foundation(NSF) Certification
 
Acceptance of foreign clinical trials.pptx
Acceptance of foreign clinical trials.pptxAcceptance of foreign clinical trials.pptx
Acceptance of foreign clinical trials.pptx
 
Regulatory approval process for invitro diagnostics in us
Regulatory approval process for invitro diagnostics in usRegulatory approval process for invitro diagnostics in us
Regulatory approval process for invitro diagnostics in us
 
GOOD AUTOMATED LABORATORY PRACTICE
GOOD AUTOMATED LABORATORY PRACTICEGOOD AUTOMATED LABORATORY PRACTICE
GOOD AUTOMATED LABORATORY PRACTICE
 

Similar to FDA Warning letter

Similar to FDA Warning letter (20)

Regulatory requirements for API and Biologics
Regulatory requirements for API and BiologicsRegulatory requirements for API and Biologics
Regulatory requirements for API and Biologics
 
What to Learn from US FDA Warning Letters and Their Impact on Pharmacovigilan...
What to Learn from US FDA Warning Letters and Their Impact on Pharmacovigilan...What to Learn from US FDA Warning Letters and Their Impact on Pharmacovigilan...
What to Learn from US FDA Warning Letters and Their Impact on Pharmacovigilan...
 
Form483 warning letter issued to pharmaceutical companies by Bindu Kshtriya
Form483 warning letter issued to pharmaceutical companies by Bindu KshtriyaForm483 warning letter issued to pharmaceutical companies by Bindu Kshtriya
Form483 warning letter issued to pharmaceutical companies by Bindu Kshtriya
 
Drug Regulatory Affairs, PPT by Sirisha Spandana rao
Drug Regulatory Affairs, PPT by Sirisha Spandana raoDrug Regulatory Affairs, PPT by Sirisha Spandana rao
Drug Regulatory Affairs, PPT by Sirisha Spandana rao
 
Regulatory requirements for drug approval .pptx
Regulatory requirements for drug approval .pptxRegulatory requirements for drug approval .pptx
Regulatory requirements for drug approval .pptx
 
A) Study in detail about Para - IV filing. B) Case studies for Para - IV Filing.
A) Study in detail about Para - IV filing. B) Case studies for Para - IV Filing.A) Study in detail about Para - IV filing. B) Case studies for Para - IV Filing.
A) Study in detail about Para - IV filing. B) Case studies for Para - IV Filing.
 
Overview of FDA Drug Manufacturing Requirements
Overview of FDA Drug Manufacturing RequirementsOverview of FDA Drug Manufacturing Requirements
Overview of FDA Drug Manufacturing Requirements
 
Pharma Uptoday MM: Volume 1 issue April 2014
Pharma Uptoday MM: Volume 1 issue April 2014 Pharma Uptoday MM: Volume 1 issue April 2014
Pharma Uptoday MM: Volume 1 issue April 2014
 
Fda gmp compliance for the Life Science Industry
Fda gmp compliance for the Life Science IndustryFda gmp compliance for the Life Science Industry
Fda gmp compliance for the Life Science Industry
 
Gui final referencing_approved _oct 2020
Gui final referencing_approved _oct 2020Gui final referencing_approved _oct 2020
Gui final referencing_approved _oct 2020
 
Handling of a fda inspection [compatibility mode]
Handling of a fda inspection [compatibility mode]Handling of a fda inspection [compatibility mode]
Handling of a fda inspection [compatibility mode]
 
5. Unit-V- Regulatory Concepts.
5. Unit-V- Regulatory Concepts.5. Unit-V- Regulatory Concepts.
5. Unit-V- Regulatory Concepts.
 
FDA Enforcement: The Cop is Back – How Enhanced Enforcement Can Impact You a...
FDA Enforcement:  The Cop is Back – How Enhanced Enforcement Can Impact You a...FDA Enforcement:  The Cop is Back – How Enhanced Enforcement Can Impact You a...
FDA Enforcement: The Cop is Back – How Enhanced Enforcement Can Impact You a...
 
guide.pdf
guide.pdfguide.pdf
guide.pdf
 
Generic Drug Labeling Proposed Rule: The Generic Drug Industry Perspective
Generic Drug Labeling Proposed Rule:  The Generic Drug Industry PerspectiveGeneric Drug Labeling Proposed Rule:  The Generic Drug Industry Perspective
Generic Drug Labeling Proposed Rule: The Generic Drug Industry Perspective
 
Why Compliance is a Tough Pill to Swallow – Nutraceuticals
Why Compliance is a Tough Pill to Swallow – NutraceuticalsWhy Compliance is a Tough Pill to Swallow – Nutraceuticals
Why Compliance is a Tough Pill to Swallow – Nutraceuticals
 
Hatch- waxman act (The drug price competition and patent term restoration act...
Hatch- waxman act (The drug price competition and patent term restoration act...Hatch- waxman act (The drug price competition and patent term restoration act...
Hatch- waxman act (The drug price competition and patent term restoration act...
 
Ind by pankaj
Ind by pankajInd by pankaj
Ind by pankaj
 
FDA Enforcement & Compliance for Medical Devices
FDA Enforcement & Compliance for Medical DevicesFDA Enforcement & Compliance for Medical Devices
FDA Enforcement & Compliance for Medical Devices
 
ANDA FDA APPLICATION
ANDA FDA APPLICATIONANDA FDA APPLICATION
ANDA FDA APPLICATION
 

More from Sridhar S (6)

TSE/BSE Evaluation
TSE/BSE EvaluationTSE/BSE Evaluation
TSE/BSE Evaluation
 
Regulatory requirements for drug approval in Saudi Arabia
Regulatory requirements for drug approval in Saudi ArabiaRegulatory requirements for drug approval in Saudi Arabia
Regulatory requirements for drug approval in Saudi Arabia
 
Plasma master file
Plasma master filePlasma master file
Plasma master file
 
Bis standards
Bis standardsBis standards
Bis standards
 
Site master file
Site master fileSite master file
Site master file
 
Fda med watch
Fda med watchFda med watch
Fda med watch
 

Recently uploaded

Spellings Wk 4 and Wk 5 for Grade 4 at CAPS
Spellings Wk 4 and Wk 5 for Grade 4 at CAPSSpellings Wk 4 and Wk 5 for Grade 4 at CAPS
Spellings Wk 4 and Wk 5 for Grade 4 at CAPS
AnaAcapella
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
heathfieldcps1
 
QUATER-1-PE-HEALTH-LC2- this is just a sample of unpacked lesson
QUATER-1-PE-HEALTH-LC2- this is just a sample of unpacked lessonQUATER-1-PE-HEALTH-LC2- this is just a sample of unpacked lesson
QUATER-1-PE-HEALTH-LC2- this is just a sample of unpacked lesson
httgc7rh9c
 

Recently uploaded (20)

Graduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - EnglishGraduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - English
 
Interdisciplinary_Insights_Data_Collection_Methods.pptx
Interdisciplinary_Insights_Data_Collection_Methods.pptxInterdisciplinary_Insights_Data_Collection_Methods.pptx
Interdisciplinary_Insights_Data_Collection_Methods.pptx
 
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdfUnit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
 
On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan Fellows
 
Spellings Wk 4 and Wk 5 for Grade 4 at CAPS
Spellings Wk 4 and Wk 5 for Grade 4 at CAPSSpellings Wk 4 and Wk 5 for Grade 4 at CAPS
Spellings Wk 4 and Wk 5 for Grade 4 at CAPS
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
 
QUATER-1-PE-HEALTH-LC2- this is just a sample of unpacked lesson
QUATER-1-PE-HEALTH-LC2- this is just a sample of unpacked lessonQUATER-1-PE-HEALTH-LC2- this is just a sample of unpacked lesson
QUATER-1-PE-HEALTH-LC2- this is just a sample of unpacked lesson
 
OSCM Unit 2_Operations Processes & Systems
OSCM Unit 2_Operations Processes & SystemsOSCM Unit 2_Operations Processes & Systems
OSCM Unit 2_Operations Processes & Systems
 
Introduction to TechSoup’s Digital Marketing Services and Use Cases
Introduction to TechSoup’s Digital Marketing  Services and Use CasesIntroduction to TechSoup’s Digital Marketing  Services and Use Cases
Introduction to TechSoup’s Digital Marketing Services and Use Cases
 
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxHMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
 
Towards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxTowards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptx
 
Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)
 
Simple, Complex, and Compound Sentences Exercises.pdf
Simple, Complex, and Compound Sentences Exercises.pdfSimple, Complex, and Compound Sentences Exercises.pdf
Simple, Complex, and Compound Sentences Exercises.pdf
 
PANDITA RAMABAI- Indian political thought GENDER.pptx
PANDITA RAMABAI- Indian political thought GENDER.pptxPANDITA RAMABAI- Indian political thought GENDER.pptx
PANDITA RAMABAI- Indian political thought GENDER.pptx
 
21st_Century_Skills_Framework_Final_Presentation_2.pptx
21st_Century_Skills_Framework_Final_Presentation_2.pptx21st_Century_Skills_Framework_Final_Presentation_2.pptx
21st_Century_Skills_Framework_Final_Presentation_2.pptx
 
How to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POSHow to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POS
 
How to Manage Call for Tendor in Odoo 17
How to Manage Call for Tendor in Odoo 17How to Manage Call for Tendor in Odoo 17
How to Manage Call for Tendor in Odoo 17
 
How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17
 
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
 
Tatlong Kwento ni Lola basyang-1.pdf arts
Tatlong Kwento ni Lola basyang-1.pdf artsTatlong Kwento ni Lola basyang-1.pdf arts
Tatlong Kwento ni Lola basyang-1.pdf arts
 

FDA Warning letter

  • 1. Presented By:- Sridhar S 1st M.Pharmacy Pharmaceutical Regulatory Affairs JSS College Of Pharmacy Mysuru-15
  • 2. DEFINITION  An FDA warning letter is an official message from the United states Food & Drugs Administration (FDA) that it has found that a manufacturer has violated some rule in a regulated activity.  While the FDA generally determines violations through its own inspections, they can also issue one based on evidence from state personnel  the FDA does not consider a warning letter a final action on which it can be issued
  • 3. The FDA defines an FDA warning letter as:-  “A correspondence that notifies regulated industry about violations that FDA has documented during its inspections or investigations.  Typically, a Warning Letter notifies a responsible individual or firm that the Agency considers one or more products, practices, processes, or other activities to be in violation of the Federal Food, Drug, and Cosmetic Act (the Act), its implementing regulations and other federal statutes.  Warning Letters should only be issued for violations of regulatory significance, i.e., those that may actually lead to an enforcement action if the documented violations are not promptly and adequately corrected. A Warning Letter is one of the Agency’s principal means of achieving prompt voluntary compliance with the Act.
  • 4.  The agency has a computer application called the Compliance Management System (CMS) that district offices use to electronically submit warning letter recommendations to FDA Centers.  All district office must use the CMS to submit the warning letter recommendation, the Form FDA 483 that supports the alleged violations, the Establishment Inspection Report (EIR), and any written response from the firm.
  • 5. WHY FDA COMES FOR INSPECTION  The person who involved in the manufacturing of bulk API or involved in the formulation of product are willing to sale or market there product in the regions of the united states  The dossier is submitted according NDA for new product and ANDA for generic drug and 502(f)(1) for an API or bulk chemical
  • 6.  After the dossier or application is accepted by the USFDA and send a reply for the inspection of the premises  FDA FORM 482- Notice Of Inspection  It is an official notice of FDA for inspection signed by the FDA officials. It is produced by the inspector and has the authority to inspect the manufacturing facility  Inspection coordinator will receive the notice and manage the inspection accordingly
  • 7.  Coordinator should ask for notice, if it is not presented by the FDA inspector  A copy of this shall be attached with the inspection file FORM 482 shows that inspector has authorization from FDA to inspect the facility  An inspector can ask for the manufacturing records of the regulated product and can enter in the area where the product is being manufactured.
  • 8.  He can review online records, collect samples and interview the personnel working in area  An inspector cant review the product price list, financial data of firm, product marketing data, research documents and employee data excluding the training records.  These documents are considered as firms confidential documents
  • 9.
  • 10.  FDA FORM 483 – Observations of inspection  Inspector shall provide the list of his observations about inspection on FORM 483  It has all the points noticed by the FDA inspectors. An observation made in previous inspection or as mentioned in the GMP are not followed or corrected can be added in 483  The original copy of the FDA Form 483 is presented to the form management, generally to the person who had received the notice of inspection
  • 11.  FDA Form 484- recipient of Samples  During the inspection if FDA inspectors want to take any sample they have to issue a receipt of those samples on Form 484  It has a quantity of simple with the lot number of the product sampled Form 484 is used for samples only but not for promotional material, labels, photographs or any record taken by FDA investigators
  • 12.
  • 13. TYPES OF WARNING LETTERS  General FDA Warning Letters  Tobacco Retailer Warning Letters  Drug Marketing and Advertising Warning Letters (and Untitled Letters to Pharmaceutical Companies)
  • 14. General FDA Warning Letters  When FDA finds that a manufacturer has significantly violated FDA regulations, FDA notifies the manufacturer. This notification is often in the form of a Warning Letter.  The Warning Letter identifies the violation, such as poor manufacturing practices, problems with claims for what a product can do, or incorrect directions for use.  The letter also makes clear that the company must correct the problem and provides directions and a timeframe for the company to inform FDA of its plans for correction.
  • 15.  FDA then checks to ensure that the company’s corrections are adequate. Matters described in FDA warning letters may have been subject to subsequent interaction between FDA and the recipient of the letter that may have changed the regulatory status of the issues discussed in the letter.
  • 16. Tobacco Retail Warning Letters  Compliance check inspections of tobacco retailers occur periodically, and are conducted to determine a retail establishment’s compliance with the Federal Food, Drug, and Cosmetic Act, as amended by the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act) and its regulations in effect  such as the Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco to Protect Children and Adolescents, found at Title 21 of the Code of Federal Regulations, Part 1140
  • 17.  21 C.F.R. Part 1140 CIGARETTES, SMOKELESS TOBACCO, AND COVERED TOBACCO PRODUCTS Prohibition of sale and distribution to the persons younger then 18yrs of age and Format and content requirements for labeling and advertising.  Tobacco products covered in compliance check inspections of tobacco retailers include cigarettes and smokeless tobacco.  All other Warning Letters issued by CTP for violations of the Federal Food, Drug, and Cosmetic Act, as amended by the Tobacco Control Act and its applicable regulations, can be found at FDA’s main Warning Letter page at the Inspections, Compliance, Enforcement, and Criminal Investigations - Warning Letters page.
  • 18. Drug Marketing and Advertising Warning Letters  These letters are supplied by the CDER Freedom of Information Office (FOI). This page only covers letters issued by Headquarters and the Office of Prescription Drug Promotion (formerly the Division of Drug Marketing, Advertising, and Communications).  "Cyber" letters are sent electronically via the Internet to web sites that offer to sell online prescription drugs that may be illegal. The letters warn these web site operators that they may be engaged in illegal activities and informs them of the laws that govern prescription drug sales.
  • 19. Warning Letter Close-Out Letter Program  (Applies to letters issued on or after Sept. 1, 2009)  FDA may issue a Warning Letter close-out letter ("close-out letter") once the Agency has completed an evaluation of corrective actions undertaken by a firm in response to a Warning Letter.  A close-out letter may issue when, based on FDA’s evaluation, the firm has taken corrective action to address the violations contained in the Warning Letter. This procedure applies to Warning Letters issued on or after September 1, 2009.
  • 20.  A close-out letter will not be issued based on representations that some action will or has been taken. The corrective actions must actually have been made and verified by FDA.  If the Warning Letter contains violations that by their nature are not correctable, then no close-out letter will issue.  Future FDA inspections and regulatory activities may further assess the adequacy and sustainability of these corrections. Should violations be observed during a subsequent inspection or through other means, enforcement action may be taken without further notice
  • 21. HOW TO BROWSE WARNING LETTERS  Use any of these "Browse" functions:  Browse Warning Letters by Company  Browse Warning Letters by Issuing Office  Browse Warning Letters by Subject  Browse Warning Letters with Response Letters  Browse Warning Letters with Closeout Letters
  • 22. REFERENCE  https://en.wikipedia.org/wiki/Form_FDA_483  http://www.pharmaguideline.com/2014/11/fda- forms-issued-in-inspections.html  https://www.fda.gov/ICECI/EnforcementActions/Wa rningLetters/ucm278624.htm  https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/c fcfr/CFRSearch.cfm?CFRPart=1140